Samsung Biologics Q2 Revenue Rises: What to Watch Next Samsung Biologics holds strong growth and margins, with analysts rating it Buy, but labor and governance risks could hurt operating profit conversion, so upside depends on margin stability. 2026년 10월 21일 English
